Propanc Biopharma Signs MOU with Avance Clinical
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 17 hours ago
0mins
Propanc Biopharma announced it has signed a memorandum of understanding with Avance Clinical. The MOU sets out the shared intent of Propanc and Avance to work together to support the clinical delivery of Propanc's Phase 1b, first-In-human clinical trial for PRP. Importantly, both parties intend to approach the collaboration in a spirit of openness, scientific rigor, and shared problem-solving, with the goal of advancing PRP efficiently from FIH into proof-of-concept and, as data supports, later-phase development. Avance Clinical is a full-service contract research organization headquartered in Australia, with extensive operations across North America, Asia Pacific, New Zealand and Europe.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PPCB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PPCB
About PPCB
Propanc Biopharma, Inc. is an Australia-based biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Propanc Signs MOU with Avance Clinical for PRP Clinical Trial
- MOU Signing: Propanc Biopharma has signed a Memorandum of Understanding with Avance Clinical to collaboratively advance the Phase 1 clinical trial of PRP, marking a significant milestone in the company's oncology treatment journey.
- Clinical Trial Design: The planned Phase 1b trial will evaluate the safety, tolerability, and preliminary clinical activity of PRP in patients with advanced cancer, potentially offering new treatment options to address significant unmet medical needs.
- Market Advantage Utilization: Avance Clinical leverages the rapid ethics approval and up to 43.5% R&D tax rebate available in Australia, providing Propanc with an accelerated pathway to clinical success, thereby enhancing the company's competitive position in the market.
- Commitment to Scientific Collaboration: Both parties are committed to collaborating in a spirit of scientific rigor and openness, aiming to efficiently advance PRP's development, reflecting a shared commitment to patient safety and scientific excellence.
See More
Propanc Biopharma Signs MOU with Avance Clinical for Cancer Trial
- MOU Signing: Propanc Biopharma has signed a Memorandum of Understanding with Australia's Avance Clinical to collaborate on the clinical delivery of PRP, its lead investigational candidate for advanced solid tumors, marking a significant milestone from preclinical development to clinical evaluation.
- Trial Design: The study is designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary clinical activity of PRP in patients with advanced cancer, potentially offering new treatment options for patients with limited alternatives.
- Market Advantage Utilization: Avance Clinical brings over 30 years of experience in early-phase oncology trials, leveraging Australia's rapid ethics approval and significant R&D tax rebates to accelerate clinical development, which Propanc aims to capitalize on through this partnership.
- Stock Split Impact: Propanc implemented a 1-for-25 reverse stock split on May 18, 2026, and despite the current stock price of $1.82, down 3.19% from the previous trading day, the company remains focused on enhancing shareholder value through its collaboration with Avance.
See More
Biotech Companies See Significant Stock Gains
- SL Science Surge: SL Science Holding Limited (SLBT) saw its stock price soar over 50% after its Nasdaq listing, closing at $5.99, reflecting strong market interest in its innovative cellular and gene therapies targeting significant unmet medical needs like pancreatic cancer and glioblastoma.
- Chemomab's Clinical Progress: Chemomab Therapeutics Ltd. (CMMB) experienced a stock increase of over 30%, closing at $2.27, as its lead drug candidate Nebokitug prepares for a Phase 3 trial in primary sclerosing cholangitis, highlighting its potential in treating fibro-inflammatory diseases.
- Propanc's Buyback Initiative: Propanc Biopharma Inc. (PPCB) announced a share repurchase program of up to $500,000, leading to a 22.92% stock increase to $1.77, indicating confidence in its cancer treatment candidate PRP and plans for a first-in-human study in advanced cancer patients.
- Tectonic's Clinical Trial Updates: Tectonic Therapeutic Inc. (TECX) saw its stock rise over 15%, closing at $37.93, as its lead candidates TX45 and TX2100 progress in clinical trials, with significant data expected in late 2026 or early 2027, potentially driving future growth.
See More
Propanc Biopharma Initiates $5M Share Repurchase Program
- Repurchase Program Launch: Propanc Biopharma has announced a $5 million share repurchase program, intending to buy back up to $500,000 worth of shares over the next 30 days, demonstrating confidence in its intrinsic value and aiming to enhance shareholder returns.
- Stock Price Surge: Following the announcement, PPCB's stock price increased by 20.14% to $1.73, reflecting a positive market sentiment regarding the company's future prospects and potentially attracting more investor interest.
- Capital Utilization Strategy: This repurchase plan not only helps reduce the number of shares outstanding but may also enhance earnings per share, thereby strengthening the company's competitive position in the capital markets and solidifying its market presence.
- Long-term Growth Signal: By implementing this repurchase program, Propanc Biopharma conveys confidence in its future growth, indicating a strategic approach to improving overall financial health through effective capital management.
See More
Propanc Biopharma Shares Surge 200% Amid Buyback Program
- Stock Surge: Propanc Biopharma (PPCB) shares soared over 200% on Thursday, marking the largest single-day gain since the 1-for-25 reverse stock split on May 18, reflecting strong investor confidence in the company's long-term potential.
- Buyback Program: The company announced a buyback program authorizing up to $5 million in repurchases, with management asserting that the current stock price does not fully reflect the company's intrinsic value and long-term potential, which could enhance shareholder value.
- Reverse Split Impact: Following the 1-for-25 reverse stock split on May 18, PPCB's outstanding shares were reduced from approximately 57 million to about 2.3 million, aimed at regaining compliance with Nasdaq's $1 minimum bid price requirement and supporting growth plans.
- R&D Developments: Propanc is currently engaged in two cancer research programs, partnering with Germany's FyoniBio to develop a pharmacokinetics assay for its lead cancer therapy candidate, while also collaborating with Spanish universities to evaluate an anti-aging compound, furthering its research in fibrosis and cancer-related patents.
See More
Propanc Biopharma Authorizes $5M Share Buyback Program
- Buyback Program Initiated: Propanc Biopharma has authorized a share repurchase program allowing for the buyback of up to $5 million in common stock, reflecting management's confidence in the company's progress, particularly in advancing its lead therapeutic candidate, PRP.
- Clinical Trial Advancement: PRP, a first-in-class therapy for metastatic cancer from solid tumors, is moving toward a pivotal Phase 1b study involving 30 to 40 advanced cancer patients, indicating significant clinical potential.
- Orphan Drug Designation: PRP has received Orphan Drug Designation from the U.S. FDA, which would grant seven years of market exclusivity upon approval, presenting substantial commercial opportunities for the company.
- Stock Buyback Strategy: CEO James Nathanielsz stated that the buyback program aims to enhance long-term shareholder value and will be executed when market conditions are favorable, demonstrating the company's belief that its shares are significantly undervalued.
See More
Propanc Signs MOU with Avance Clinical for PRP Clinical Trial
- MOU Signing: Propanc Biopharma has signed a Memorandum of Understanding with Avance Clinical to collaboratively advance the Phase 1 clinical trial of PRP, marking a significant milestone in the company's oncology treatment journey.
- Clinical Trial Design: The planned Phase 1b trial will evaluate the safety, tolerability, and preliminary clinical activity of PRP in patients with advanced cancer, potentially offering new treatment options to address significant unmet medical needs.
- Market Advantage Utilization: Avance Clinical leverages the rapid ethics approval and up to 43.5% R&D tax rebate available in Australia, providing Propanc with an accelerated pathway to clinical success, thereby enhancing the company's competitive position in the market.
- Commitment to Scientific Collaboration: Both parties are committed to collaborating in a spirit of scientific rigor and openness, aiming to efficiently advance PRP's development, reflecting a shared commitment to patient safety and scientific excellence.
See More
Propanc Biopharma Signs MOU with Avance Clinical for Cancer Trial
- MOU Signing: Propanc Biopharma has signed a Memorandum of Understanding with Australia's Avance Clinical to collaborate on the clinical delivery of PRP, its lead investigational candidate for advanced solid tumors, marking a significant milestone from preclinical development to clinical evaluation.
- Trial Design: The study is designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary clinical activity of PRP in patients with advanced cancer, potentially offering new treatment options for patients with limited alternatives.
- Market Advantage Utilization: Avance Clinical brings over 30 years of experience in early-phase oncology trials, leveraging Australia's rapid ethics approval and significant R&D tax rebates to accelerate clinical development, which Propanc aims to capitalize on through this partnership.
- Stock Split Impact: Propanc implemented a 1-for-25 reverse stock split on May 18, 2026, and despite the current stock price of $1.82, down 3.19% from the previous trading day, the company remains focused on enhancing shareholder value through its collaboration with Avance.
See More
Biotech Companies See Significant Stock Gains
- SL Science Surge: SL Science Holding Limited (SLBT) saw its stock price soar over 50% after its Nasdaq listing, closing at $5.99, reflecting strong market interest in its innovative cellular and gene therapies targeting significant unmet medical needs like pancreatic cancer and glioblastoma.
- Chemomab's Clinical Progress: Chemomab Therapeutics Ltd. (CMMB) experienced a stock increase of over 30%, closing at $2.27, as its lead drug candidate Nebokitug prepares for a Phase 3 trial in primary sclerosing cholangitis, highlighting its potential in treating fibro-inflammatory diseases.
- Propanc's Buyback Initiative: Propanc Biopharma Inc. (PPCB) announced a share repurchase program of up to $500,000, leading to a 22.92% stock increase to $1.77, indicating confidence in its cancer treatment candidate PRP and plans for a first-in-human study in advanced cancer patients.
- Tectonic's Clinical Trial Updates: Tectonic Therapeutic Inc. (TECX) saw its stock rise over 15%, closing at $37.93, as its lead candidates TX45 and TX2100 progress in clinical trials, with significant data expected in late 2026 or early 2027, potentially driving future growth.
See More
Propanc Biopharma Initiates $5M Share Repurchase Program
- Repurchase Program Launch: Propanc Biopharma has announced a $5 million share repurchase program, intending to buy back up to $500,000 worth of shares over the next 30 days, demonstrating confidence in its intrinsic value and aiming to enhance shareholder returns.
- Stock Price Surge: Following the announcement, PPCB's stock price increased by 20.14% to $1.73, reflecting a positive market sentiment regarding the company's future prospects and potentially attracting more investor interest.
- Capital Utilization Strategy: This repurchase plan not only helps reduce the number of shares outstanding but may also enhance earnings per share, thereby strengthening the company's competitive position in the capital markets and solidifying its market presence.
- Long-term Growth Signal: By implementing this repurchase program, Propanc Biopharma conveys confidence in its future growth, indicating a strategic approach to improving overall financial health through effective capital management.
See More
Propanc Biopharma Shares Surge 200% Amid Buyback Program
- Stock Surge: Propanc Biopharma (PPCB) shares soared over 200% on Thursday, marking the largest single-day gain since the 1-for-25 reverse stock split on May 18, reflecting strong investor confidence in the company's long-term potential.
- Buyback Program: The company announced a buyback program authorizing up to $5 million in repurchases, with management asserting that the current stock price does not fully reflect the company's intrinsic value and long-term potential, which could enhance shareholder value.
- Reverse Split Impact: Following the 1-for-25 reverse stock split on May 18, PPCB's outstanding shares were reduced from approximately 57 million to about 2.3 million, aimed at regaining compliance with Nasdaq's $1 minimum bid price requirement and supporting growth plans.
- R&D Developments: Propanc is currently engaged in two cancer research programs, partnering with Germany's FyoniBio to develop a pharmacokinetics assay for its lead cancer therapy candidate, while also collaborating with Spanish universities to evaluate an anti-aging compound, furthering its research in fibrosis and cancer-related patents.
See More
Propanc Biopharma Authorizes $5M Share Buyback Program
- Buyback Program Initiated: Propanc Biopharma has authorized a share repurchase program allowing for the buyback of up to $5 million in common stock, reflecting management's confidence in the company's progress, particularly in advancing its lead therapeutic candidate, PRP.
- Clinical Trial Advancement: PRP, a first-in-class therapy for metastatic cancer from solid tumors, is moving toward a pivotal Phase 1b study involving 30 to 40 advanced cancer patients, indicating significant clinical potential.
- Orphan Drug Designation: PRP has received Orphan Drug Designation from the U.S. FDA, which would grant seven years of market exclusivity upon approval, presenting substantial commercial opportunities for the company.
- Stock Buyback Strategy: CEO James Nathanielsz stated that the buyback program aims to enhance long-term shareholder value and will be executed when market conditions are favorable, demonstrating the company's belief that its shares are significantly undervalued.
See More
